When I asked I used the term 'not clear' and I'll give them the benefit of the doubt the terms 'acts via a unique mechanism of action' and 'differs from the mechanism of currently used anti hepatitis agents', because this might be correct for all we know. However, nowhere in the PR the term 'NS3/4A protease inhibitor' is mentioned and in this omission lies a possible intent to mislead. I hope to explain this to them sometime because I do appreciate the people and the company and they have been impeccable so far or I wouldn't have looked at nor touched BLRX ever.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.